Australian Prostate Cancer Research Centre - Queensland (APCRC-Q)

Overview

The Australian Prostate Cancer Research Centre – Queensland (APCRC-Q) is a transdisciplinary research centre, focused on the development of prostate cancer therapeutics and prognostic biomarkers and their translation into clinical practice. The Centre is a joint initiative between QUT and the Princess Alexandra Hospital and will relocate to the Translational Research Institute in late 2012.

The work of the Centre is organised into the following five platforms to deliver outcomes at each stage of a translational pipeline from discovery through to clinical testing of potential treatments:

  • High Throughput Bioprofiling and Bioinformatics
  • Molecular Pathology
  • Functional Genomics: Characterisation and Model Systems
  • Preclinical Imaging and Therpauetic Development
  • Multidiciplinary Clinical Trials and Advanced Health Delivery.

The Centre has strong national and international affiliations and linkages to connect its researchers and information with relevant expertise and resources worldwide.

APCRC-Q is the the Australian hub of the Australian-Canadian Prostate Cancer Research Alliance which facilitates access to unique resources, clinical trials networks, and leading edge infrastructure.

http://www.australianprostatecentre.org/

Research leader
Research team
QUT External collaborators
Organisational unit
Lead unit Institute of Health and Biomedical Innovation Other units
Research area
Cancer
Keywords
apcrc – q, apcrc-q, australian prostate cancer research centre – queensland, prostate cancer, prostate cancer research

Contact

Contact the research leader for more information.

 

Partnerships

The Australian Prostate Cancer Research Centre – Queensland is one of two disease-specific, consolidated national prostate cancer research centres.

The Centre is a joint initiative between the Queensland University of Technology and the Princess Alexandra Hospital.

Publications and output

In the period January to June 2012, the following papers were published:

  • Gunter JH, Lubik AA, McKenzie I, Pollak M, Nelson CC (2012) The interactions between insulin and androgens in progression to castrate resistant prostate cancer. Advances in Urology. 2012;2012:248607. Epub 2012 Apr 3 DOI: 10.1155/2012/248607.
  • Jeet V, Russell PJ, Verma N, Khatri A. (2012) Targeting aurora kinases: A novel approach to curb the growth and chemoresistance of androgen refractory prostate cancer. Current Cancer Drug Targets. 2012 Feb;12(2):144-163.
  • Rutkowski R, Mertens-Walker I, Lisle JE, Herington AC, Stephenson SA. (2012) Evidence for a dual function of EphB4 in tumour promotion and suppression regulated by the absence or presence of the ephrinB2 ligand. International Journal of Cancer. 2012 Sep 1;131(5):E614-24. DOI: 10.1002/ijc PMID: 22161689, ePub Jan 2012.
  • Wilkinson R, Woods K, D’Rozario R, Prue R, Vari F, Hardy MY, Dong Y, Clements JA, Hart DNJ, Radford KJ. (2012) Human Kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients. Cancer Immunology Immunotherapy. 2012 Feb;61(2):169-79.
  • Inder KL, Zheng YZ, Davis M, Moon H, Loo D, Nguyen H, Clements J, Parton RG, Foster LJ, Hill MM. (2012) Expression of PTRF in PC3 cells modulates cholesterol dynamics and the actin cytoskeleton impacting secretion pathways. Molecular & Cellular Proteomics. 2012 Feb;11(2):M111.012245.
  • Ling MT, Luk SU, Ai-Ejeh F, Khanna KK. (2012) Tocotrienol as potential anticancer agent. Carcinogenesis. 2012 Feb;33(2):233-9.
  • Lose F, Lawrence MG, Srinivasan S, O’Mara T, Marquart L, Chambers S, Gardiner RA, Aitken JF, Spurdle AB, Batra J, Clements JA, the Australian Prostate Cancer BioResource. (2012) Kallikrein 14 is down-regulated by androgen receptor signalling and harbours genetic variation that is associated with prostate tumour aggressiveness. Biol Chem, 4th International Kallikrein Symposium Special Issue. 2012 Apr 1;393:403-412.
  • Xiao J, Liong EC, Ling MT, Ching YP, Fung ML, Tipoe GL. (2012) S-allylmercaptocysteine reduces carbon tetrachloride-induced hepatic oxidative stress and necroinflammation via nuclear factor kappa B-dependent pathways in mice. European Journal of Nutrition. 2012 Apr;51(3):323-33.
  • Jingjing Y,Cozzi P, Fitzgerald A, Walsh B, Russell PJ, Willcox M,GrahamP, Li Y. (2012) Prostate Cancer Biomarkers and the Emerging Proteomic Techniques Used in Biomarker Research. June 2012, Chapter 1 in Horizons in Cancer Research, Volume 47, Editor: Watanabe HS, ISBN 978-1-61470-444-7.

For prior publications, please consult individual researcher profiles.